COLLEGIUM PHARMACEUTICAL, INC
Close on Oct 19, 2026
- Market cap
- $746.92M
- P/E (TTM)
- 18.6
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $199.90M | $-0.46 | $1.92 |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | $193.50M | $0.40 | $1.76 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | $205.40M | $0.46 | $2.04 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | $209.40M | $0.84 | $2.25 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | $188.00M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | $177.80M | $0.07 | $1.49 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | After market close | $181.90M | $0.36 | $1.75 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | $159.30M | $0.27 | $1.61 |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 29, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 22, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDAnon-GAAP | full-year 2026 | $445.00M to $470.00M | Lowered |
| Product Revenues, Net | full-year 2026 | $825.00M to $855.00M | Raised |
| JORNAY PM Revenue, Net | full-year 2026 | $190.00M to $200.00M | Lowered |
| AZSTARYS Revenue, Net | full-year 2026 | $65.00M to $75.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Collegium Pharmaceutical filed with the SEC
Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q2 2026 Earnings Report August 6, 2026 | Nasdaq: COLL Healthier people. Stronger communities.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Collegium Completes Acquisition of AZSTARYS ®
Acquisition or disposition completed · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q1 2026 Earnings Report May 7, 2026 | Nasdaq: COLL Healthier people. Stronger communities.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Collegium to Acquire AZSTARYS® from Corium
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Collegium to Acquire AZSTARYS ® from Corium Therapeutics March 19, 2026 | Nasdaq: COLL Healthier people. Stronger communities.
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q4 and FY2025 Earnings Report February 26, 2026 | Nasdaq: COLL Healthier people. Stronger communities.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Collegium Provides 2026 Financial Guidance and
Regulation FD disclosure · EX-99.1 to Form 8-K
January 2026 | Nasdaq: COLL
Regulation FD disclosure · EX-99.2 to Form 8-K
Announces the Closing of $980 Million Syndicated Credit Facility
Material agreement · Agreement terminated · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
November 6, 2025 | Nasdaq: COLL
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
August 7, 2025 | Nasdaq: COLL
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
May 8, 2025 | Nasdaq: COLL
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
February 27, 2025 | Nasdaq: COLL
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Collegium Provides 2025 Financial Guidance and
Regulation FD disclosure · EX-99.1 to Form 8-K
Investor Presentation January 2025 | Nasdaq: COLL Healthier people. Stronger communities.
Regulation FD disclosure · EX-99.2 to Form 8-K
Collegium Reports Record Third Quarter 2024
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
November 7, 2024 | Nasdaq: COLL
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Collegium Appoints Vikram Karnani as Chief Executive
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.3 to Form 8-K
Collegium Completes Acquisition of Ironshore
Acquisition or disposition completed · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Investor Presentation September 2024 | Nasdaq: COLL
Acquisition or disposition completed · New financial obligation · Regulation FD disclosure · EX-99.2 to Form 8-K
Collegium Reports Second Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
August 8, 2024 | Nasdaq: COLL
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Collegium to Acquire Ironshore Therapeutics,
Material agreement · Results of operations · New financial obligation · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Collegium to Acquire Ironshore Therapeutics July 29, 2024 | Nasdaq: COLL
Material agreement · Results of operations · New financial obligation · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Collegium Obtains Six Month Extension of U.S.
Other events · EX-99.1 to Form 8-K
Collegium Reports First Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
May 9, 2024 | Nasdaq: COLL
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Collegium Pharmaceutical, Inc. Announces Redemption
Other events · EX-99.1 to Form 8-K
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
February 22, 2024 | Nasdaq: COLL
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Collegium Provides 2024 Financial Guidance
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Investor Presentation January 2024 | Nasdaq: COLL
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Collegium Reports Third Quarter 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K